期刊文献+

预混胰岛素、二甲双呱、吡格列酮联合治疗初诊2型糖尿病效果观察 被引量:2

下载PDF
导出
摘要 目的探讨预混胰岛素、二甲双呱、吡格列酮联合治疗初诊2型糖尿病的远期效果。方法选择2007~2010年186例初诊2型糖尿病进行为期3个月的预混胰岛素、二甲双呱、吡格列酮联合治疗,比较治疗前后空腹血糖、空腹血清C肽、餐后2h血糖、餐后2h血清C肽、糖化血红蛋白及不用服药1年的血糖达标率等指标并对结果进行分析。结果联合治疗后空腹血糖、血清C肽及餐后2h血糖、血清C肽、糖化血红蛋白与治疗前比较差异有显著性(P〈0.05)。不用服药1年的血糖达标率为51.61%(96例)。结论预混胰岛素、二甲双呱、吡格列酮联合治疗初诊2型糖尿病可明显改善患者胰岛8细胞的分泌功能。
作者 周全 黄绍鹏
出处 《右江民族医学院学报》 2012年第4期475-476,共2页 Journal of Youjiang Medical University for Nationalities
  • 相关文献

参考文献8

  • 1陆再英,钟南山,谢毅,等.内科学[M].7版.北京:人民卫生出版社,2010:125-126.
  • 2Kilpatrick ED,Robertson RP.Differentiation between glu-cose-induced desensitization of insulin secretion and beta-cell exhaustion in the HIT-T15 cell line[J].Diabetes,1998,47(4):606-611.
  • 3Leahy JL,Bonner-Wweir S,Weir GC.β-cell dysfunctioninduced by chronic hyperglycemia.Current ideas on mecha-nism of impaired glucose-induced insulin secretion[J].Di-abetes Care,1992,15(3):442-455.
  • 4Sivitz WI.Lipotoxicity and glucotoxicity in type 2 diabetes.Effects on development and progression[J].Postgrad Med,2001,109(4):55-59,63-64.
  • 5Alvarsson M,Sundkvist G,Lager I,et al.Beneficial effectsof insulin versus sulphyonylurea on insulin secretion andmetabolic control in recently diagnosed type 2 diabetic pa-tients[J].Diabetes Care,2003,26(8):2231-2237.
  • 6翁建平,许雯.B细胞功能与2型糖尿病的预防和治疗[J].国外医学(内分泌学分册),2003,23(3):182-183. 被引量:59
  • 7Lingvay I,Kaloyanova PF,Adams-Huet B,et al.Insulinas initial therapy in type 2 diabetes:effective,safe,and wellaccepted[J].J Investig Med,2007,55(2):62-68.
  • 8李焱,梁骏,梁颖,刘珊英,陈黎红,杨川,徐明彤,严励,程桦,傅祖植.三种胰岛素强化治疗方案的短期疗效和安全性比较[J].中华内分泌代谢杂志,2008,24(6):620-622. 被引量:54

二级参考文献12

  • 1毕宇芳,宁光,孙首悦,周莹霞,洪洁,刘建民,赵咏桔,李小英,王卫庆.Aspart与正规人胰岛素应用胰岛素泵控制血糖的疗效比较[J].中华内分泌代谢杂志,2006,22(3):266-267. 被引量:12
  • 2李光伟,宁光,周智广.2型糖尿病早期胰岛素强化治疗改善胰岛β细胞功能——是现实还是梦想?[J].中华内分泌代谢杂志,2006,22(4):309-312. 被引量:223
  • 3张波,安雅莉,巩秋红,帅英,卜石,陈燕燕,张金苹,杨文英,刘雪丽,李光伟.短期胰岛素强化治疗诱导2型糖尿病患者长期缓解的预测因素[J].中华内分泌代谢杂志,2007,23(2):134-138. 被引量:95
  • 4Ilkova H, Glaster B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type of 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20 : 1253- 1356.
  • 5Garber A J, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab, 2006, 8:58-66.
  • 6Hirsch IB. Insulin Analogues. N Engl J Med, 2005,352:174-183.
  • 7Rosenstoek J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine ( HOE 901 ) and NPH insulin. Diabetes Care, 2001,24:631-636.
  • 8Heinemann L, Linkeschova R, Rave K. Time-action profile of the longacting insulin analog insulin glargine ( HOE901 ) in comparison with those of NPH insulin and placebo. Diabetes Care, 2000,23:644-649.
  • 9Boehm BO, Vaz JA, Biondsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Int Med, 2004, :496-502.
  • 10Beohm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med, 2002,19:393-399.

共引文献139

同被引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部